Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy

por Ishihara, Hisamitsu, Yamaguchi, Susumu, Sugitani, Toshifumi, Kosakai, Yoshinori
Publicado 2019

Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibit...

por Kashiwagi, Atsunori, Shoji, Shingo, Onozawa, Satoshi, Kosakai, Yoshinori, Waratani, Miina, Ito, Yuichiro
Publicado 2022

Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A...

por Kashiwagi, Atsunori, Shoji, Shingo, Kosakai, Yoshinori, Koga, Tadashi, Asakawa, Keiko, Rokuda, Mitsuhiro
Publicado 2022

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials

por Kashiwagi, Atsunori, Yoshida, Satoshi, Nakamura, Ichiro, Kazuta, Kenichi, Ueyama, Eiji, Takahashi, Hideyuki, Satomi, Hayato, Kosakai, Yoshinori, Kawamuki, Kosei
Publicado 2016